ERBB2 and breast carcinoma: Seven of these mutations were activating mutations and all of these mutations were sensitive to the irreversible HER2/EGFR tyrosine kinase inhibitor neratinib, thus validating HER2 somatic mutations as drug targets for breast cancer treatment (Bose et al., 2013).